Chordia Therapeutics ＜190A＞ announced on the 26th that it will present research results related to CDK12 inhibitors, which is the company's pipeline, at the 47th Japanese Molecular Biology Society mini-symposium and poster session to be held at Marinemesse Fukuoka.
The company is a research and development type bioventure specialized in the cancer area with clinically developed products, and is working on research and development of multiple pipelines, such as the CLK inhibitor rogocekib, the CDK12 inhibitor CTX-439, and GCN2 inhibitors.
The title of this presentation is “Interaction between CDK12 and NXF1 involved in DNA damage responses.” We report that CDK12 inhibitors target RNA regulatory stress via “RNA transport” in addition to known “transcription,” and that “RNA transport” can affect the extent of anticancer effects of CDK12 inhibitors. These findings are expected to lead to the identification of biomarkers that can predict the effects of CDK12 inhibitors in the future.
